Monopar ALXN1840 Phase 3 Data Improves Wilson Disease Outcomes

Wilmette, Illinois, USA, April 19, 2026

In a significant advancement for rare disease therapeutics, Monopar Therapeutics Inc. has presented compelling Phase 3 clinical data demonstrating that its investigational therapy ALXN1840 (tiomolibdate choline) delivers superior neurologic outcomes compared to standard of care (SoC) in patients with Wilson disease. The findings, showcased at the 2026 American Academy of Neurology (AAN) Annual Meeting, highlight the therapy’s potential to address a critical unmet need in patients suffering from neurologic manifestations of this rare genetic disorder, which is caused by toxic copper accumulation in the body.

ALXN1840 Demonstrates Superior Neurologic Benefits

The Phase 3 FoCus trial evaluated ALXN1840 in patients with neurologic symptoms at baseline, comparing its performance against existing standard treatments. The results showed significantly greater neurologic improvement and reduced disease worsening in patients treated with ALXN1840 over a 48-week period. Notably, only 9% of patients receiving ALXN1840 experienced clinically meaningful neurologic worsening, compared to 25% in the standard-of-care group, while 45% of ALXN1840-treated patients showed neurologic improvement, outperforming the 32% improvement rate observed with standard therapies.

Additional clinical measures, including Clinical Global Impression (CGI) scores, further confirmed superior outcomes, with 61% improvement in disease severity and 47% improvement in overall clinical status, significantly higher than comparator groups. These findings underscore the therapy’s ability to deliver clinically meaningful and durable neurologic benefits in a patient population with limited treatment options.

Durable Efficacy and Favorable Safety Profile

Beyond short-term outcomes, ALXN1840 demonstrated sustained long-term benefits, with neurologic improvements continuing to increase over approximately three years of treatment, highlighting its potential for disease-modifying effects. The therapy also exhibited a favorable safety and tolerability profile, with low rates of serious adverse events (4.9%) and no treatment-related deaths, reinforcing its suitability for long-term use in chronic disease management. Importantly, the benefits were consistent across both treatment-naïve and previously treated patients, indicating broad applicability across the Wilson disease population. This durability and safety profile position ALXN1840 as a strong candidate for first-line or replacement therapy in managing neurologic complications of the disease.

Advancing Toward Regulatory Approval and Market Impact

The promising Phase 3 results support Monopar’s plans to submit a New Drug Application (NDA) to the U.S. FDA in mid-2026, marking a critical step toward potential commercialization. Wilson disease, affecting approximately 1 in 30,000 individuals globally, remains a challenging condition with limited effective treatments, particularly for patients with neurologic symptoms.

ALXN1840’s novel mechanism of action, which involves binding and neutralizing excess copper while preventing its toxic effects, addresses the root cause of the disease. If approved, the therapy could significantly improve clinical outcomes, quality of life, and long-term prognosis for patients. Monopar’s continued advancement of ALXN1840 reflects its commitment to delivering innovative treatments for underserved patient populations, further strengthening its position in the rare disease biopharma sector.

Overall, the Phase 3 FoCus trial results mark a pivotal milestone in the treatment of Wilson disease, demonstrating that ALXN1840 has the potential to transform the standard of care by delivering superior neurologic benefits, durable efficacy, and strong safety outcomes. This development represents a meaningful step forward in addressing the unmet needs of patients living with this debilitating and life-threatening condition.

Source: Monopar Therapeutics press release